Preliminary Phase II Data on Millennium's Proteasome Inhibitor MLN341 Hold Promise for Patients With Multiple Myeloma

In this article Millennium Pharmaceuticals, Inc. updated preliminary findings of a phase II clinical trial of its investigational drug MLN341 (formerly known as LDP-341 and PS-341) in patients with multiple myeloma, the second most common hematologic cancer, whose disease has relapsed and not responded following multiple prior treatments. The study results showed that MLN341 stabilized or reduced myeloma (M) protein, a primary marker of cancer burden, in the majority of study participants, with manageable and predictable side effects. In addition, the majority of patients did not experience disease progression during the 24 week study.

Provided by: Millennium Pharmaceuticals Topic: Software Date Added: May 2002 Format: HTML

Find By Topic